These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29017950)

  • 1. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
    Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
    Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
    Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
    J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
    Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.
    Bajbouj K; Mawrin C; Hartig R; Schulze-Luehrmann J; Wilisch-Neumann A; Roessner A; Schneider-Stock R
    J Neurooncol; 2012 May; 107(3):503-16. PubMed ID: 22270849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
    Wu Y; Guo SW
    Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
    Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
    Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
    Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
    Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
    Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
    Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
    Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
    Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
    Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H
    Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
    Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
    Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
    Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
    Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells.
    Duncan HF; Smith AJ; Fleming GJ; Cooper PR
    J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
    Zhao X; Yang W; Shi C; Ma W; Liu J; Wang Y; Jiang G
    Tumour Biol; 2011 Apr; 32(2):335-46. PubMed ID: 21113745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid in the complex therapy of malignant tumors.
    Hrebackova J; Hrabeta J; Eckschlager T
    Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
    Sanchez-Gonzalez B; Yang H; Bueso-Ramos C; Hoshino K; Quintas-Cardama A; Richon VM; Garcia-Manero G
    Blood; 2006 Aug; 108(4):1174-82. PubMed ID: 16675713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.